Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 42 (4), 327-60

Pharmacokinetics and Pharmacodynamics of Cannabinoids


Pharmacokinetics and Pharmacodynamics of Cannabinoids

Franjo Grotenhermen. Clin Pharmacokinet.


Delta(9)-Tetrahydrocannabinol (THC) is the main source of the pharmacological effects caused by the consumption of cannabis, both the marijuana-like action and the medicinal benefits of the plant. However, its acid metabolite THC-COOH, the non-psychotropic cannabidiol (CBD), several cannabinoid analogues and newly discovered modulators of the endogenous cannabinoid system are also promising candidates for clinical research and therapeutic uses. Cannabinoids exert many effects through activation of G-protein-coupled cannabinoid receptors in the brain and peripheral tissues. Additionally, there is evidence for non-receptor-dependent mechanisms. Natural cannabis products and single cannabinoids are usually inhaled or taken orally; the rectal route, sublingual administration, transdermal delivery, eye drops and aerosols have only been used in a few studies and are of little relevance in practice today. The pharmacokinetics of THC vary as a function of its route of administration. Pulmonary assimilation of inhaled THC causes a maximum plasma concentration within minutes, psychotropic effects start within seconds to a few minutes, reach a maximum after 15-30 minutes, and taper off within 2-3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30-90 minutes, reach their maximum after 2-3 hours and last for about 4-12 hours, depending on dose and specific effect. At doses exceeding the psychotropic threshold, ingestion of cannabis usually causes enhanced well-being and relaxation with an intensification of ordinary sensory experiences. The most important acute adverse effects caused by overdosing are anxiety and panic attacks, and with regard to somatic effects increased heart rate and changes in blood pressure. Regular use of cannabis may lead to dependency and to a mild withdrawal syndrome. The existence and the intensity of possible long-term adverse effects on psyche and cognition, immune system, fertility and pregnancy remain controversial. They are reported to be low in humans and do not preclude legitimate therapeutic use of cannabis-based drugs. Properties of cannabis that might be of therapeutic use include analgesia, muscle relaxation, immunosuppression, sedation, improvement of mood, stimulation of appetite, antiemesis, lowering of intraocular pressure, bronchodilation, neuroprotection and induction of apoptosis in cancer cells.

Similar articles

  • [The Effects of Cannabis and THC]
    F Grotenhermen. Forsch Komplementarmed 6 Suppl 3, 7-11. PMID 10575282. - Review
    Cannabis and THC exert manifold actions on a number of organ systems. A lethal dose of THC in humans is unknown. Above the psychotropic threshold, ingestion of cannabis c …
  • Pharmacology of Cannabinoids
    F Grotenhermen. Neuro Endocrinol Lett 25 (1-2), 14-23. PMID 15159677. - Review
    Dronabinol (Delta 9-tetrahydocannabinol, THC), the main source of the pharmacological effects caused by the use of cannabis, is an agonist to both the CB1 and the CB2 sub …
  • Cannabinoids
    F Grotenhermen. Curr Drug Targets CNS Neurol Disord 4 (5), 507-30. PMID 16266285. - Review
    Since the discovery of an endogenous cannabinoid system, research into the pharmacology and therapeutic potential of cannabinoids has steadily increased. Two subtypes of …
  • Cannabis and Cannabinoids: Pharmacology and Rationale for Clinical Use
    RG Pertwee. Forsch Komplementarmed 6 Suppl 3, 12-5. PMID 10575283. - Review
    It is now known that there are at least two types of cannabinoid receptors. These are CB1 receptors, present mainly on central and peripheral neurones, and CB2 receptors, …
  • [Cannabis and Cannabinoids as Drugs]
    HZ Khiabani et al. Tidsskr Nor Laegeforen 127 (5), 579-82. PMID 17332810. - Review
    It has been demonstrated that mammalian tissues express cannabinoid receptors (CB1, CB2 and most probably CB3) and endogenous ligands for these. Knowledge of these recept …
See all similar articles

Cited by 203 PubMed Central articles

See all "Cited by" articles


    1. Neuroreport. 2002 Apr 16;13(5):567-70 - PubMed
    1. Arch Gen Psychiatry. 2001 Oct;58(10):909-15 - PubMed
    1. Mol Pharmacol. 1993 Nov;44(5):1008-15 - PubMed
    1. Chem Phys Lipids. 2000 Nov;108(1-2):191-209 - PubMed
    1. Clin Pharmacol Ther. 1982 May;31(5):617-24 - PubMed

LinkOut - more resources